Benchmarking inappropriate empirical antibiotic treatment  by Kariv, G. et al.
Benchmarking inappropriate empirical antibiotic treatment
G. Kariv1,2, M. Paul2,3, V. Shani1,2, E. Muchtar1,2 and L. Leibovici1,2
1) Department of Medicine E, Rabin Medical Centre, Beilinson Hospital, Petah-Tikva, Israel 2) Sackler Faculty of Medicine, Tel-Aviv University, Petah-Tikva,
Israel and 3) Unit of Infectious Diseases, Rabin Medical Centre, Beilinson Hospital, Petah-Tikva, Israel
Abstract
Inappropriate empirical antibiotic treatment for severe infections is associated with increased mortality. Superfluous treatment is associ-
ated with resistance induction. We aimed to define acceptable rates of inappropriate empirical antibiotic treatment. We included all
prospective cohort studies published between 1975 and 2009 reporting the proportion of appropriate and inappropriate empirical anti-
biotic treatment of microbiologically documented infections. Studies were identified in PubMed and in reference lists of included studies.
Funnel plots were drawn using the proportion of inappropriate empirical treatment as the effect size. A pooled estimate of inappropri-
ate empirical antibiotic treatment was calculated using a b-binomial model. Control limits were calculated with the overdispersion factor
technique and 20% winsorized data. Heterogeneity was assessed through subgroup analysis for categorical moderators and meta-regres-
sion for continuous variables. Eighty-seven studies, comprising 92 study groups, with 27 628 patients met inclusion criteria. The pooled
rate of inappropriate empirical antibiotic treatment was 28.6% (95% CI 25.4–31.8). Funnel plot analysis yielded a dispersed graph with
only 37 (40%) studies falling within the control limits. Using the overdispersion factor technique with 20% winsorizing, 79 (86%) studies
fell within the control limits. None of the clinical or methodological factors could explain the large heterogeneity observed. The funnel
plot presented can be used to benchmark rates of inappropriate empirical antibiotic treatment. Based on the control limits found, at
least 500 patients should be evaluated before establishing a local rate. Lower and higher than expected rates might indicate overly
aggressive treatment or poor performance, respectively.
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Introduction
Inappropriate antibiotic usage affects both the single patient
and the community. From the single patient perspective,
inappropriate empirical antibiotic treatment is associated
with a significant increase in mortality [1]. From the commu-
nity perspective, superfluous antibiotic use leads to economic
cost and, more importantly, an ecological problem of resis-
tant bacteria induction [2]. Therefore, empirical antibiotic
treatment of suspected moderate to severe bacterial infec-
tion does not aim at 100% coverage of all possible patho-
gens, but is an attempt to strike a balance between coverage
and the ecological impact of broad-spectrum antibiotics [3].
We aimed to examine whether this balance is uniform in dif-
ferent practices.
We reviewed studies reporting on the rate of inappropri-
ate empirical antibiotic treatment for documented bacterial
infections, following a predefined protocol. We performed a
meta-analysis of inappropriate empirical treatment rates. Our
aim was to define an acceptable range of rates based on cur-
rently reported rates and to assess whether there are fac-
tors that underlie a justified deviation from the acceptable
range. These results can be used to benchmark appropriate-
ness of empirical antibiotic treatment.
Methods
Data sources
We searched PubMed for studies looking at the percentage
of empirical antibiotic treatment. Prospective studies (defined
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as those where at least data collection was performed pro-
spectively) published between 1975 and 2009 were included
if addressing adults (‡18 years) with microbiologically docu-
mented infections and treatment was selected by clinicians.
Studies where treatment was defined by study protocol or
those addressing patients treated with specific antibiotics
were excluded. The definition of appropriate empirical anti-
biotic treatment was treatment that was given before the
results of the cultures were known and matched the in vitro
susceptibility of the pathogen. We permitted the inclusion of
studies where up to 10% of microbiologically documented
infections cannot be tested in vitro; in these cases the study
definitions for appropriateness were accepted. We excluded
studies assessing meningitis, endocarditis or viral infections;
and studies that recruited <50 patients or were published in
languages other than English. We used the following search
clause: ((antibiot* OR antimicrob* OR anti-bacter* OR anti-
bacter*) AND (approp* OR inapprop* OR adequate OR inad-
equate)) AND ((cohort* OR prospect*) NOT retrospect*)
NOT Review[ptyp] AND ‘adult’[MeSH Terms]. References
from identified studies were also scanned.
Data extraction
Two reviewers independently extracted the data from
included studies. In case of any disagreement between the
two reviewers, a third reviewer extracted the data and con-
sensus was reached. We extracted data on appropriate
empirical treatment (definition, timing of treatment, number
of appropriate and/or inappropriate treated patients). In
addition, we extracted data on study characteristics to allow
the examination of factors affecting the rate of inappropriate
empirical antibiotic treatment. We collected data on settings,
study years, study objectives, follow-up duration, patient
characteristics, pathogens and source of infection. In cases
where data were published in multiple studies, the data were
included only once.
Data synthesis and analysis
The pooled estimate of inappropriate empirical antibiotic
treatment was calculated using various methods, including
fixed and random effects models, simple binomial model and
b-binomial model. Fixed and random effects models were per-
formed using COMPREHENSIVE META ANALYSIS version 2.2, Simple
binomial and b-binomial calculations were performed using
SAS software and SAS BETABIN MACRO (http://www.
qistats.co.uk/BetaBinomial.html). Funnel plots were drawn
using the proportion of inappropriate empirical treatment as
the effect size. The funnel plot graph uses five lines. The cen-
tral horizontal line is the pooled proportion estimate.
The selected model for the pooled proportion estimate was
the b-binomial model. This model is proposed for combining
overdispersed binomial data across multiple, heterogeneous
studies [4]. The upper and lower lines present the control lim-
its, calculated as 2 SD and 3 SD (95% and 99.8% prediction
limits). Control limits are calculated using the overdispersion
factor technique and 20% winsorized data [5]. Any point falling
outside the control limits is an outlier, suggesting a special
cause for the variation. The funnel plots were prepared based
on a funnel plot EXCEL template downloaded from Easter
Region Public Health Observatory (ERPHO, http://www.er-
pho.org.uk/).
Analysing the cause for variation of the effect size used sub-
group analysis for categorical moderators and meta-regression
for continuous variables (Comprehensive Meta-analysis Version
2, Biostat, Englewood, NJ, USA (2005)). Correlation analysis
between variables was performed using SPSS (version PASW
STATISTICS 17.0, Release 17.0.2, SPSS Inc., Chicago, IL, USA).
Results
The search for potentially eligible studies yielded 1053 refer-
ences. Eighty-seven studies reporting rate of inappropriate
empirical treatment and meeting the inclusion criteria were
included (Fig. 1). These publications comprised 92 study
Search for eligible studies (n = 1053) 
• electronic search of PubMed (n = 960) 
• scan of references of identified studies (n = 93) 
Studies excluded (n = 966) 
• Retrospective 
• Less than 50 patients 
• Duplicate publications 
• Incompatible definitions
(appropriate, empirical treatment)  
• Not written in English 
• Treatment defined in advance 
• Assessment of meningitis,
endocarditis or viral only  
Included studies (n = 87) 
Included study groups (n = 92) 
FIG. 1. Study flow.
TABLE 1. Pooled rates of inappropriate empirical antibiotic
treatment
Method Estimate (%) Lower 95% CI Upper 95% CI
Simple binomial 29.19 28.65 29.72
b-Binomial 28.65 25.45 31.85
Meta-analysis (fixed) 31.4 30.8 32
Meta-analysis (random) 26.3 23.7 29
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groups, which were used to develop the pooled estimate
and the funnel plot. The studies are described in Appendix
S1 and referenced separately (Appendix S2).
The studies included a total of 27 628 patients and were
published between 1977 and 2007. The studies were carried
out in 23 different countries, predominated by Spain with 34
studies and USA with 24 studies (only a few studies were
multi-centred, Appendix S1). Forty-one studies (45%) were
conducted in an intensive-care unit (ICU) and the remaining
studies were carried out exclusively or predominantly in a
non-ICU setting. Forty-six studies (50%) assessed bactera-
emia, 24 (26%) assessed pneumonia and the remainder
assessed a mix of microbiologically documented infections.
Most (71, 77%) of the studies evaluated pathogens combined,
but 15 (16%) and 6 (7%) focused on gram-negative and
gram-positive infections, respectively.
The reported proportions of inappropriate empirical
treatment varied from 1.61% to 77.36%. Significant heteroge-
neity between studies was observed (I2 = 95.6%, p <0.001).
The random effect meta-analysis yielded a pooled proportion
of inappropriate treatment of 26.3% (95% CI 23.7–29).
Results for the pooled proportion in the different models
are presented in Table 1. The pooled proportion estimate
used in the funnel plot is the b-binomial calculated average,
28.6% (95% CI 25.4–31.8). Data presented using a funnel plot
yielded a dispersed graph with only 37 (40%) of the studies
falling within the control limits. When using the overdisper-
sion factor technique with winsorizing of 20%, a more suit-
able funnel plot was produced, leaving only a few studies as
outliers (Table 2 and Fig. 2).
We assessed the effects of various study characteristics on
results. These included demographic variables (coun-
try—divided into low, medium and high prevalence of resis-
tant pathogens, age, ICU or non-ICU, place of acquisition),
pathogen, type of infection and percentage of bacteraemia,
study methods (design, primary aim and appropriate defini-
tion) and years of data collection (Appendix S1). The propor-
tion of inappropriate empirical treatment was associated only
with the rate of infections caused by gram-negative bacteria
in the study with borderline statistical significance (increase
of 1.006, 95% CI 1–1.012; for a 1% increase in gram-negative
infections, p 0.05), mixed effect meta-regression. None of the
other variables could explain the heterogeneity in reported
rates of inappropriate empirical treatment.
Discussion
The objective of this study was to calculate and present, based
on the available literature, a method for benchmarking inap-
propriate empirical antibiotic treatment. A pooled estimate
rate of 28.65% inappropriately treated patients was calculated
from 87 prospective studies, comprising 27 628 patients, with
highly significant heterogeneity. Using the funnel plot
TABLE 2. Comparison between presented funnel plots
Within limits (%) Below 2r (%) Above 2r (%) Below 3r (%) Above 3r (%)
Basic funnel plot 37 (40) 12 (13) 6 (7) 18 (20) 19 (21)
Overdispersion, 20% winsorized 79 (86) 5 (5) 2 (2) 2 (2) 4 (4)
Data are presented as number of studies (%).
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FIG. 2. Funnel plot using overdispersion fac-
tor, 20% winsorized. The plot presents the
percentage of inappropriate empirical anti-
biotic treatment against the study size.
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technique, only 40% of studies fell within the 95% confidence
limits of the pooled rate estimate. We could not explain the
heterogeneity between rates in individual studies using a large
dataset of the cohort characteristics. Specifically, the rate of
inappropriate treatment did not change during the last dec-
ades; and was not dependent on the severity or type of infec-
tion (except for a marginally significant influence of the
percentage of gram-negative infections). We therefore used
the overdispersion factor technique to incorporate the heter-
ogeneity in the benchmark funnel plot. Winsoring of 20% was
necessary to obtain a funnel plot where 86% of studies fell
within the 95% confidence limits of the pooled rate.
Quality control and performance measurement is gaining
focus in healthcare. Measures are used to answer questions
like ‘How are we doing?’, ‘What should we be doing?’ and
‘Have the changes we have made led to improvement?’ [6].
A funnel plot is a graphical tool mainly used for detecting
bias in meta-analysis [7]. A funnel plot is a chart in which
data of interest (the indicator/proportion) are plotted against
a denominator representing the precision such as volume,
sample size or size of the study cohort. In addition, control
limit lines are drawn, creating the funnel. In recent years fun-
nel plots have been proposed as one of the preferred tools
for quality control and performance comparisons [8–15].
Their main advantages over other methods are that they do
not promote ranking, they accommodate variable sample
sizes, and the data are visually displayed for an intuitive inter-
pretation. When presenting data in a funnel plot, common
versus special cause variation is intuitively presented,
whereas using a table to show the same data would promote
‘best’ and ‘worst’ values.
This paper presents a practical and reliable method for
benchmarking the rate of inappropriate empirical antibiotic
treatment. The method relies on a large amount of data
being available and on robust statistical methods. There are
several limitations to our analysis. We could not find reasons
for the large heterogeneity. Causes can range from data
quality issues to local resistance profile or quality of care.
We analysed many variables extracted from the studies as
possible moderators, but each was tested separately in uni-
variate analysis. Perhaps a mix of several variables (e.g. study
carried out in ICU in recent years) is needed to explain het-
erogeneity. Our inclusion criteria can be contested. We
aimed to include all studies whose primary, prospectively
defined, objective was to examine the rate or effect of inap-
propriate empirical antibiotic treatment. We probably missed
studies reporting rates as part of other research objectives.
The included studies are not necessarily representative: they
were performed in hospitals with an interest in the topic
and with the resources to conduct prospective studies and
with an interest in publishing them. Many small studies
reported a low rate of inappropriate treatment, and we can-
not rule out publication bias.
Further research should address healthcare organization
volume and superfluous antibiotic usage. We believe that the
funnel plot generated here can be used as the start of a
benchmarking effort by hospitals that aim to test their antibi-
otic practice. Use of ongoing databases might provide better
data for benchmarking than the use of published data.
The funnel plot can also be used to test the adequacy of
antibiotic treatment in trials of antibiotic and non-antibiotic
treatment of patients with septicaemia. A small cohort will
defeat the purpose of the funnel plot, as the confidence
intervals are wide for small numbers. The 95% CI bound-
aries for a cohort of 500 patients are 15–42%, and we rec-
ommend using a cohort of at least 500 patients for
benchmarking.
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